Hilltop Partners LLC Raises Stock Holdings in Johnson & Johnson $JNJ

Hilltop Partners LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,419 shares of the company’s stock after acquiring an additional 3,453 shares during the quarter. Johnson & Johnson makes up about 0.8% of Hilltop Partners LLC’s holdings, making the stock its 23rd largest position. Hilltop Partners LLC’s holdings in Johnson & Johnson were worth $2,661,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank boosted its holdings in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in Johnson & Johnson by 9.4% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 361,775 shares of the company’s stock worth $59,997,000 after purchasing an additional 31,232 shares in the last quarter. LeConte Wealth Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $467,000. Finally, Ethos Financial Group LLC lifted its stake in Johnson & Johnson by 213.4% in the 1st quarter. Ethos Financial Group LLC now owns 17,984 shares of the company’s stock worth $2,743,000 after purchasing an additional 12,245 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $211.65 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $196.09 and its two-hundred day moving average price is $177.42. The stock has a market capitalization of $509.93 billion, a price-to-earnings ratio of 20.43, a PEG ratio of 2.36 and a beta of 0.36. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $212.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Ratings Changes

A number of equities analysts have weighed in on JNJ shares. Barclays upped their target price on Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Raymond James Financial boosted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Guggenheim lifted their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Scotiabank began coverage on Johnson & Johnson in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price objective on the stock. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $207.55.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.